+41 91 682 20 40 info@elixi-int.com

Onpattro (patisiran), a new drug that addresses unmet medical need for treatment of hereditary transthyretin amyloidosis

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Onpattro (patisiran), for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy (a condition in…

Read More

AbbVie Receives U.S. FDA Approval of ORILISSA (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis

AbbVie , a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc., announced that the U.S. Food and Drug Administration (FDA) approved ORILISSA (elagolix), the first and only oral gonadotropin-releasing hormone (GnRH) antagonist specifically developed for women with moderate…

Read More

Third Novartis Phase III trial shows Kisqali (ribociclib) combination therapy significantly improves PFS in HR+/HER2- advanced breast cancer

Novartis has announced positive results from the third Phase III trial of Kisqali (ribociclib) in advanced or metastatic breast cancer. MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human…

Read More

Genentech Announces Submission of Supplemental New Drug Application for Venclexta (venetoclax) for People With Previously Untreated Acute Myeloid Leukemia who are Ineligible for Intensive Chemotherapy

Genentech has announced submission of a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) for Venclexta (venetoclax), in combination with a hypomethylating agent or in combination with low dose cytarabine (LDAC), for treatment of people with previously…

Read More
  • 1
  • 2